Listed by the USPTO as KONOPELSKI SNAVEL, SARA ELIZABETH
Tech Center 1600 • Art Units: 1654 1658
This examiner grants 35% of resolved cases
KONOPELSKI SNAVEL, SARA ELIZABETH is assigned to tech center 1600 and art unit 1654. The record contains 40 resolved cases, an allowance rate of 35.0%, and a median of 1376 days to allowance. The allowance rate indicates that allowance was less frequent in the available record, while the median reflects extended prosecution timing. The limited volume makes broad conclusions inappropriate.
The interview lift is 35.4%, indicating a positive association between interviews and allowance. Practitioners may consider interviews when a direct discussion could clarify claim scope or the application of prior art. The listed companies are Caregen Co., Ltd., Nuritas Limited, and Novo Nordisk A/S. The associated firms are Clark+Elbing LLP, BakerHostetler, and Nixon Peabody LLP.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19378410 | SEMAGLUTIDE IN THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE | Non-Final OA | Novo Nordisk A/S |
| 17785561 | STRUCTURALLY-STABILIZED ONCOLYTIC PEPTIDES AND USES THEREOF | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18258720 | PESTICIDAL HEXATOXIN POLYPEPTIDES AND METHODS OF USE THEREOF | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18030996 | NANOPARTICLE FOR ANTI-CANCER PEPTIDES AND USES THEREOF | Non-Final OA | KING'S COLLEGE LONDON |
| 18448427 | Peptide Sequences And Compositions At Air-Aqueous Interfaces For Lanthanide Recovery | Final Rejection | Northwestern University |
| 18799107 | De novo designed sequence-specific DNA binding proteins | Non-Final OA | University of Washington |
| 17487661 | BIODEGRADABLE MICRONEEDLE SYSTEM WITH SUSTAINED RELEASE | Final Rejection | University of Connecticut |
| 17788847 | AGENT FOR ADJUVANT THERAPY | Non-Final OA | TAIHO PHARMACEUTICAL CO., LTD. |
| 18447414 | INTRAVENOUS ADMINISTRATION OF ENGINEERED ANTIMICROBIAL AMPHIPHILIC PEPTIDES | Final Rejection | Peptilogics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy35.0% of resolved applications examined by Sara Elizabeth Konopelski Snavel were allowed (40 resolved cases), compared with 48.5% across Art Unit 1654 over the last five years.
This examiner's interview lift is +35.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Sara Elizabeth Konopelski Snavel took 1,376 days on average from filing to allowance.
Sara Elizabeth Konopelski Snavel examines applications in Art Unit 1654 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
